Cyclacel Pharmaceuticals Inc

NASDAQ:CYCC   3:59:42 PM EDT
0.73
-0.04 (-5.17%)
7:54:29 PM EDT: $0.74 +0.01 (+0.79%)
Earnings Announcements

Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results

Published: 11/09/2022 21:18 GMT
Cyclacel Pharmaceuticals Inc (CYCC) - Cyclacel Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update.
Cyclacel Pharmaceuticals Inc- Oral Fadraciclib Daily Dosing Well Tolerated in 18 Evaluable Patients Treated in Dose-escalation of Phase 1/2 Trial.
Cyclacel Pharmaceuticals Inc- Expect to Determine Recommended Phase 2 Dose for Oral Fadraciclib and Start Phase 2 in 1q 2023.
Cyclacel Pharmaceuticals Inc- Cash Runway to End of 2023.
Cyclacel Pharmaceuticals Inc - Qtrly Loss per Share $0.42.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.44

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.70

More details on our Analysts Page.